The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients using GnRH analogues for endometriosis it has been postulated that peripheral and inflammation-induced in-situ aromatization of adrenal androgens are probably the main reasons for the high rates of failure during follow-up. We hypothesized that in cases with premenopausal severe endometriosis, use of a combination of anastrozole and goserelin to achieve almost maximal endocrine blockade of estrogen synthesis after conservative surgery may increase the pain-free interval and reduce the recurrence rates as compared to goserelin alone. METHODS: In a prospective randomized trial, we evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endometriosis. The primary outcome measures were the symptom recurrence rates and the impact of treatment on endometriosis-related multidimensional score. The secondary outcome measures were the impact of allocated treatment regimens on menopausal quality of life and on lumbar spine bone mineral density (BMD). RESULTS: When we analyzed the Kaplan-Meier survival curves, we detected a statistically significant advantage of goserelin plus anastrozole as compared to goserelin only, in terms of the median time to detect symptom recurrence (>2.4 versus 1.7 months; log-rank test; P=0.0089). This statistically significant advantage occurred with a relative risk of 4.3 [95% confidence interval (CI) 1.3-9.8]. Three cases out of 40 recurred in the goserelin plus anastrozole arm (7.5%), whereas we detected recurrences in 14 cases out of 40 cases in the goserelin-only arm (35%) during the follow-up period of 24 months. Based on these data, the interpretation of Kaplan-Meier curves indicates that at the end of follow-up, 54.7 versus 10.4%, respectively, of the patients were free of recurrence. The mean of the differences in terms of Deltabaseline-24 months post-medical therapy multidimensional score were statistically significant in favour of goserelin and anastrozole (9.2 +/- 2.1 versus 6.7 +/- 2.8; paired t-test; P<0.0001; 95% CI 1.5-4.0). We observed a statistically significant difference in suppression of estradiol concentrations and a significantly greater BMD loss at the end of treatment in the goserelin and anastrozole arm as compared to goserelin-only arm. However, this did not elicit deterioration in menopausal quality of life and the observed bone loss was not significant in terms of DeltaBMD between the groups at 2 years of treatment withdrawal. CONCLUSIONS: Six months of treatment with anastrozole and goserelin as compared to goserelin alone increased the pain-free interval and decreased symptom recurrence rates in patients following surgery for severe endometriosis. Furthermore, menopausal quality of life and BMD at 2 years after medical therapy remained unaffected.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only one study, showed a longer interval before recurrence of symptoms during the 24-month follow-up: recurrence was registered in only 3/40 (8%) of patients in the combined arm (AI + goserelin) compared to 14/40 (35%) in the goserelin-only arm ( 26 ).”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [26]
In the citing paper
“Anastrozole (1 mg/day), administered in conjunction with goserelin for 6 months in patients with severe baseline endometriosis (rASRM score >40), showed greater improvement in pain Total Pelvic Symptom Score (TPSS) than patients using goserelin alone (ΔTPSS-P baseline -24 months PMT 5.0 vs. 3.3 p<0.0001) ( 26 ).”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [26]
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
Alexeeva, L. P., Burkhardt, P., Christiansen, C., Cooper, C. C., Delmas, P. D., Johnell, O., Johnston, C. C., Kanis, J. A., Lips, P. T. A. M., Melton, L. J., et al. (1994) · Cited by 2,655
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800 · cited 2×
“Aromatase inhibitors given alone are not able to completely inhibit ovarian steroidogenesis (Vignali et al., 2002), and, furthermore, may increase follicular recruitment (Mitwally and Casper, 2001) and may lead to ovarian stimulation and cyst formation.”
BackgroundInfluentialConstructing a standard climacteric scale
Greene, J. G. (1998) · Maturitas · doi:10.1016/s0378-5122(98)00025-5 · Cited by 657 · cited 2×
“The modi®ed Greene scale was used to determine the severity of vasomotor, somatic, psychological symptoms (anxiety and depression) and loss of sexual interest (Greene, 1998).”
MethodDeterminants of bone density in normal women: risk factors for future osteoporosis?
Stevenson, J. C., Lees, B., Devenport, M., Cust, M. P., & Ganger, K. F. (1989) · BMJ · doi:10.1136/bmj.298.6678.924 · Cited by 406 · cited 2×
“Furthermore, the physiological bone loss of 0.5% per year that is evident after the third decade should also be taken into account (Stevenson et al., 1989).”
BackgroundInfluentialTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270 · cited 4×
“In the statistical analysis of the secondary outcome variables, intentionto-treat analysis (Archer and Pickar, 2002) was used; thus, it included the dropouts for whom data are not available at 24 months after postsurgical medical treatment.”
BackgroundMethodInfluentialDosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267 · cited 2×
“…it is recommended that postoperative adjuvant treatment should be instituted in order to minimize the risk of recurrence and to extend the pain-free period after conservative surgery in cases of severe endometriosis (American College of Obstetrics and Gynecology, 1999; Gambone et al., 2002).”
BackgroundMethodAromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target
Zeitoun, K. M., & Bulun, S. E. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00393-3 · Cited by 256 · cited 2×
“In the statistical analysis of the secondary outcome variables, intentionto-treat analysis (Archer and Pickar, 2002) was used; thus, it included the dropouts for whom data are not available at 24 months after postsurgical medical treatment.”
MethodCompston, J. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.7.548 · Cited by 252
LING, F. W. (1999) · Obstetrics & Gynecology · doi:10.1097/00006250-199901000-00012 · Cited by 223 · cited 2×
“necessary in accordance with the recent literature (Hornstein et al., 1997; American College of Obstetrics and Gynecology, 1999; Ling, 1999; Vercellini et al., 1999; Winkel, 2000; Gambone et al., 2002).”
Result
Cited by
Items 101–200 of 227
New treatment strategies and emerging drugs in endometriosis
Streuli, I., de Ziegler, D., Borghese, B., Santulli, P., Batteux, F., & Chapron, C. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.668885 · Cited by 27
“One randomized trial evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for endometriosis [79].”
MethodEndometriosis and ovulatory menstruation: beyond the Sampson principle
Bulun, S. E. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188787 · Cited by 31
“The Journal of Clinical Investigation”
The role of peripheral nerve signaling in endometriosis
Godin, S. K., Wagner, J. A., Huang, P. S., & Bree, D. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00063 · Cited by 56
Endometriosis: alternative methods of medical treatment
López, J. S. J., Muñoz-Hernando, L., Marques, L. M., Alvarez-Conejo, C., Tejerizo-García, A., González, G. L., Muñoz, E. V., Jiménez, Á. M., & Muñoz-González, J. L. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s78829 · Cited by 34
Medical treatment of endometriosis.
(2008) · PubMed · Cited by 26
Are aromatase inhibitors effective in endometriosis treatment?
Colette, S., & Donnez, J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.581226 · Cited by 26
“endometriotic lesions, but to test their impact on endometriosis recurrence rates [99,100], on success of IVF/ICSI cycles [100] and on pain scores [101] after conservative surgery.”
BackgroundMethodEmerging drugs for endometriosis
Guo, S.-W. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802548360 · Cited by 24
“The only randomized clinical trial comparing GnRH-a and GnRH-a plus anastrozole (an AI) as a postsurgical regimen shows that, at the end of 24th month, the women receiving the latter treatment had a lower recurrence risk (43 vs 90%) than those receiving the former [115] .”
BackgroundCommittee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice
(2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001484 · Cited by 25
Physiology and Pathology of the Female Reproductive Axis
Bulun, S. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00017-4 · Cited by 34
Emerging treatment of endometriosis
Elnashar, A. M. (2015) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2014.12.002 · Cited by 24
A review of phase II and III drugs for the treatment and management of endometriosis
Perrone, U., Evangelisti, G., Laganà, A. S., Bogliolo, S., Ceccaroni, M., Izzotti, A., Gustavino, C., Ferrero, S., & Barra, F. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2296080 · Cited by 20
“%) during a 24-month follow-up [85].”
Role of medical treatment of endometriosis
Martone, S., Troìa, L., Marcolongo, P., & Luisi, S. V. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04784-5 · Cited by 18
Simsa, P., Mihalyi, A., Kyama, C. M., Mwenda, J. M., Fülöp, V., & D’Hooghe, T. M. (2007) · Women s Health · doi:10.2217/17455057.3.5.617 · Cited by 20
“6 mg/day Calcium 600 mg Vitamin D 400 IU Decreased pain [64]”
BackgroundInnovations in conservative endometriosis treatment: an updated review.
Ruhland, B., Agic, A., Krampe, J., Diedrich, K., & Hornung, D. (2011) · PubMed · Cited by 23
Mercorio, A., Giampaolino, P., Romano, A., Dällenbach, P., & Pluchino, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.950866 · Cited by 16
Buggio, L., Lazzari, C., Monti, E., Barbàra, G., Berlanda, N., & Vercellini, P. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4448-z · Cited by 18
Li, Z., Zhang, H. Y., Zhu, Y. J., Hu, Y. J., & Qu, P. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.10.022 · Cited by 20
“GnRHa in pain control and reducing the risk of recurrence in women undergoing surgery for endometriosis are widely available in the published reports [9–11].”
BackgroundEndometriosis: An Update on Management
Bernardi, L. A., & Pavone, M. E. (2013) · Women s Health · doi:10.2217/whe.13.24 · Cited by 16
Traitements médicaux des tumeurs ovariennes présumées bénignes
Thomin, A., Daraï, É., & Chabbert‐Buffet, N. (2013) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2013.09.032 · Cited by 17
“[87] Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T.”
BackgroundEndometriosis: associations with menopause, hormone replacement therapy and cancer
Palep-Singh, M., & Gupta, S. (2009) · Menopause international · doi:10.1258/mi.2009.009041 · Cited by 17
“In a randomized controlled trial (RCT) by Soysal et al. (2004) of 80 premenopausal women with endometriosis,”
BackgroundAcién, P., Velasco, I., & Acién, M. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01347-9 · Cited by 16
“Sample size Based on previously published studies using AI [3, 4, 12, 13] or LNG-IUD [9], in the research project-protocol of the clinical trial ENDOMET-IA-DIULNG08 (EudraCT No.”
MethodMikuš, M., Goldštajn, M. Š., Laganà, A. S., Vukorepa, F., & Ćorić, M. (2023) · Pharmaceuticals · doi:10.3390/ph16091315 · Cited by 20
“Furthermore, in postoperative surveillance, a combination of AIs with GnRH agonists for 6 months showed better results than GnRH agonists monotherapy in increasing the pain-free interval [78].”
BackgroundEfficacy of letrozole in treatment of endometriosis-related pain
Madny, E. H. (2013) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2013.04.007 · Cited by 15
Update in Female Reproduction: A Life-Cycle Approach
Barbieri, R. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0752 · Cited by 19
“The combination of goserelin plus anastrozole produced significantly greater reported pain relief than goserelin alone (33).”
BackgroundThe long road of drug development for endometriosis – Pains, gains, and hopes
Liao, Z., Monsivais, D., & Matzuk, M. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.036 · Cited by 17
Bulun, S. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00025-1 · Cited by 19
Rosenberger, D. C., Mennicken, E., Schmieg, I., Medkour, T., Péchard, M., Sachau, J., Fuchtmann, F., Birch, J. V., Schnabel, K., Vincent, K., et al. (2024) · Pain · doi:10.1097/j.pain.0000000000003290 · Cited by 16
Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis
El-Gizawy, Z., Tzakas, E., & O’Brien, P. M. S. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01972.x · Cited by 12
Khayat, S., Elliott, B., & Dahan, M. H. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1519790 · Cited by 11
“by symptom disappearance or recurrence [15].”
Naem, A., Krentel, H., Moawad, G., Naem, J., Venezia, R., Etrusco, A., Terzic, S., & Laganà, A. S. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2024.102500 · Cited by 15
Aromatase Inhibitors: Potential Reproductive Implications
Bedaiwy, M. A., Mousa, N. A., & Casper, R. F. (2009) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2009.05.009 · Cited by 11
Place des nouveaux traitements médicaux dans l’endométriose douloureuse, RPC Endométriose CNGOF-HAS
Legendre, G., Delbos, L., Hudon, E., Chabbert‐Buffet, N., Geoffron, S., Sauvan, M., Fernandez, H., Bouet, P., & Descamps, P. (2018) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2018.02.009 · Cited by 19
Wang, X., Wu, P., Li, X., Zeng, C., Zhu, J., Zhou, Y., Lu, Y. F., & Xue, Q. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.666195 · Cited by 13
Audebert, A. J. M. (2006) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2006.01.038 · Cited by 11
Experimental Treatments of Endometriosis
Attar, R., & Attar, E. (2015) · Women s Health · doi:10.2217/whe.15.51 · Cited by 8
Potential cures for endometriosis
Jacobson, T. Z. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05933.x · Cited by 9
Investigational drugs for endometriosis
Chlouber, R. O., Olive, D. L., & Pritts, E. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.4.399 · Cited by 8
“Aromatase inhibitors have also been used successfully in combination with other established modalities, such as oral progesterone [14] and GnRH agonists [15].”
MethodMedical treatments of endometriosis: a review
Elbasueny, B., Geerts, M., Yang, E. C., Allaire, C., Yong, P. J., & Bedaiwy, M. A. (2022) · Reproductive and Developmental Medicine · doi:10.1097/rd9.0000000000000053 · Cited by 12
Organization of the Cytoskeleton in Ectopic Foci of the Endometrium with Rare Localization
Александрович, Т. К., Povorova, V. V., Gorbacheva, E. Y., Boyarintsev, V. V., & Ogneva, I. V. (2021) · Biomedicines · doi:10.3390/biomedicines9080998 · Cited by 8
“Estrogen promotes the survival of endometrial cells in ectopic foci, the inflammatory response and disease progression [29,30], while aromatase inhibitors significantly reduce the severity of disease symptoms [31,32].”
BackgroundRacine, A.-C., Legrand, É., Lefebvre-Lacoeuille, C., Hoppé, E., Català, L., Sentilhes, L., & Descamps, P. (2010) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2010.03.005 · Cited by 10
Medical treatment of endometriosis: an update
Ezzat, L. (2017) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20174193 · Cited by 7
“A randomized trial of women on goserelin treated with anastrozole or placebo reported no difference in symptom scores during treatment, but the anastrozole group had a lower recurrence rate as well as a longer time to symptom recurrence.(33) However, anastrozole increased bone loss compared with goserelin alone.”
Safety of current strategies to manage moderate to severe pain in patients with endometriosis
Ferrero, S., Barra, F., Vatteroni, G., Rosato, F. P., Evangelisti, G., Paudice, M., & Vellone, V. G. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2547017 · Cited by 10
“The combination therapy led to greater pain reduction and a longer recurrence-free interval during a two-year follow-up [102].”
Yıldırım, G., Attar, R., Fıçıcıoğlu, C., Karateke, A., Özkan, F., Kılıç, E., Yılmaz, B., & Yeşildağlar, N. (2009) · Europe PMC (PubMed Central) · Cited by 6
Geoffron, S., Legendre, G., Daraï, É., & Chabbert‐Buffet, N. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.10.005 · Cited by 7
Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review
Rotenberg, O. D., Kuo, D. Y.-S., & Goldberg, G. L. (2021) · Climacteric · doi:10.1080/13697137.2021.1990259 · Cited by 6
“AIs were also found to improve pain in refractory cases and to reduce the number of postoperative recurrences [23,24].”
BackgroundGupta, R. K., Agrawal, C. S., Yadav, R. P., Uprety, D., & Sah, P. L. (2011) · Journal of Nepal Medical Association · doi:10.31729/jnma.249 · Cited by 5
Genetic Polymorphisms Associated with Endometriosis in Pakistani Women
Liaqat, I., Jahan, N., Lone, K. P., PAKSTIS, A. J., & Taylor, H. S. (2013) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000165 · Cited by 5
“Stromal cells derived from women with endometriosis produce large quantities of prostaglandin E2, which induce local estrogen biosynthesis and exacerbate pelvic pain (8).”
BackgroundPreparation and in vitro/in vivo evaluation of anastrozole reservoir‐type intravaginal ring
Xia, L., Qiu, S., Liu, Z., & Ning, M. (2018) · Biomedical Chromatography · doi:10.1002/bmc.4459 · Cited by 5
Medical Therapy of Endometriosis
Kang, A. R., & Hur, J. Y. (2010) · Journal of Korean Medical Association · doi:10.5124/jkma.2010.53.5.424 · Cited by 5
Diagnostic value of the plasmatic ADM level for early ectopic pregnancy.
Yan, Q. J., Lu, Q., Tao, Y., Wang, Y., & Zhao, W. (2015) · PubMed Central · Cited by 5
Osteoporosis Associated with Cancer Therapy
Heras-Herzig, A., Kozlow, W., Brown, S. A., & Guise, T. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50056-2 · Cited by 5
Viganò, P., Rabellotti, E., Pagliardini, L., Somigliana, E., Candiani, M., & Vercellini, P. (2012) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-012-0013-8 · Cited by 5
Graham, P. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.14.2347 · Cited by 4
“3 Endometriosis Endometriosis is another endocrine-dependent pathology for which anastrozole in combination with goserelin has shown superiority over goserelin alone following surgical debulking of severe endometriosis [83] .”
BackgroundMedical Therapies: Aromatase Inhibitors
Bulun, S. E., Attar, E., Gürateş, B., Chen, Y., Tokunaga, H., Monsivais, D., & Pavone, M. E. (2011) · Wiley eBooks · doi:10.1002/9781444398519.ch35 · Cited by 5
Bonanni, R., Ratano, P., Cariati, I., Tancredi, V., & Cifelli, P. (2024) · Biomolecules · doi:10.3390/biom14121627 · Cited by 4
“In addition, positive results have been obtained in the treatment of lesions in randomized controlled trials evaluating the efficacy of aromatase inhibitors [117,118], selective estrogen receptor modulators [119], anti-inflammatory agents [120], and immunomodulators [121].”
Aromatase Expression in Endometriosis and Its Significance
Ishikawa, H., & Shozu, M. (2014) · Springer eBooks · doi:10.1007/978-4-431-54421-0_11 · Cited by 3
Immunologic Aspects of Endometriosis
Young, A. N., Maghsoudlou, P., King, L. P., Rogers, M. S., & Hornstein, M. D. (2024) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-024-00373-2 · Cited by 3
“When used in combination with gonadotropin-releasing hormone (GnRH) analogs, compared to GnRH analogs alone, one clinical trial showed combination treatment of aromatase inhibitor and GnRH analog resulted in longer-lasting pain relief [200].”
Ferrero, S., Remorgida, V., & Venturini, P. L. (2010) · Europe PMC (PubMed Central) · Cited by 5
Anti-cancer Drugs in Endometriosis Management: Mechanisms and Therapeutic Potential
Neykhonji, M., Al-Asady, A. M., Akbarzadeh, H., Avan, A., Khazaei, M., & Hassanian, S. M. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128387356250720042300 · Cited by 2
Endometriosis: Diagnosis and Treatment: From Fingernails to the Robot
Buescher, E., & NEZHAT, C. R. (2012) · Cureus · doi:10.7759/cureus.68 · Cited by 2
“The combination of anastrozole plus goserelin can be used to reduce pain and reduce recurrences [44-45].”
BackgroundThe use of aromatase inhibitors in infertility and gynecology
Al-Shalati, J., & Tulandi, T. (2011) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.11.30 · Cited by 2
FACULTE MIXTE DE MEDECINE ET DE PHARMACIE DE ROUEN
Eltchaninoff, H., Lacroix, D., & Savoure, D. A. (2013) · Cited by 2
Ashraf, S., Khosa, A. F., & Farwa, R. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22166307 · Cited by 3
Hormonal Therapy in Endometriosis and Adenomyosis: Danazol, Aromatase Inhibitors
Ferrero, S., & Barra, F. (2022) · Springer eBooks · doi:10.1007/978-3-030-97236-3_42 · Cited by 4
Opoku‐Anane, J., Tyan, P., Klebanoff, J. S., Clay, J., & Moawad, G. (2018) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-018-0246-2 · Cited by 2
Der derzeitige Stand der konservativen Therapie der Endometriose
Urdl, W. (2006) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 3
Aromatase et endométriose : mythe ou réalité ?
Colette, S., & Donnez, J. (2010) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2010.03.014 · Cited by 2
Acién, P., Velasco, I., & Acién, M. (2019) · Preprints.org · doi:10.20944/preprints201911.0010.v1 · Cited by 2
Silva, A. L. A., Caetano, I. M., Milagres, D. C., Filho, A. S. S., Noviello, M. B., & Caetano, P. L. M. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n1-056 · Cited by 2
Medikamentöse Therapie der Endometriose
Burghaus, S., & Beckmann, M. W. (2024) · Die Gynäkologie · doi:10.1007/s00129-024-05198-x · Cited by 1
Wu, Y., Dai, Y., Shi, J., Lyu, S., Gu, Z., Zhang, C., Yan, H., Leng, J., & Li, X. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology X · doi:10.1016/j.eurox.2024.100349 · Cited by 2
“Previous studies have reported a recurrence rate of ovarian endometrioma after conservative laparoscopic surgery of 29 – 89.6 % at 2 years and 15.1 – 56 % at 5 years [10 – 13].”
InfluentialMedical Management of Endometriosis
Fedele, L., Bianchi, S., Fontana, E., Berlanda, N., Frontino, G., & Bulfoni, A. (2006) · Women s Health · doi:10.2217/17455057.2.2.297 · Cited by 1
“Soysal and colleagues conducted a prospective, randomized trial comparing a combination of anastrozole and goserelin for 6 months with goserelin alone for 6 months after conservative surgery for severe endometriosis [60].”
BackgroundGOSERELIN ACETATE FOR RECURRENT ENDOMETRIOSIS
AL-Azzawy, M. A. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
How to Protect Fertility Potential in Endometriosis
Begum, M. R., Ehsan, M., Ehsan, N., & Rashid, F. (2024) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-2380 · Cited by 1
Alternative Therapieoptionen bei Endometriose
Arndt, D., Bobermien, K., Heyer, H., & Hinken, B. (2007) · Der Gynäkologe · doi:10.1007/s00129-007-2016-5 · Cited by 1
Hormonal Treatment of Bowel Endometriosis
Ferrero, S., Barra, F., Loddo, A., & Attar, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-50446-5_16 · Cited by 2
Endometriosis: Pathogenesis and Management of Pain
Kulp, J. L., & Arici, A. M. (2011) · Wiley eBooks · doi:10.1002/9781444391855.ch4 · Cited by 1
Medikamentöse Therapie der Endometriose
Schäfer, S. D. (2013) · Der Gynäkologe · doi:10.1007/s00129-013-3218-7 · Cited by 1
Endometriosis and ovarian reserve : Inflammation and prognostic markers
Falconer, H. (2008) · Figshare · Cited by 1
Molecular profiling of human endometrium and endometriosis
Huhtinen, K. (2010) · UTUPub (University of Turku) · Cited by 2
Surgical Management Options for Patients with Infertility and Endometriosis
Catenacci, M., & Falcone, T. (2010) · Current Women s Health Reviews · doi:10.2174/157340410791321363 · Cited by 1
Khazali, S., Dimitriou, E. N., & Wright, J. T. (2009) · Gynecological Surgery · doi:10.1007/s10397-009-0480-8 · Cited by 1
Schindler, A. E. (2009) · Gynecological Endocrinology · doi:10.3109/09513590903080928 · Cited by 1
Medikamentöse Therapie der chronischen Endometriose
Schäfer, S. D., & Kiesel, L. (2011) · Gynäkologische Endokrinologie · doi:10.1007/s10304-011-0441-y
Firnhaber, S. (2007) · DuEPublico (University of Duisburg-Essen) · Cited by 1
Possible additional therapeutic uses of aromatase inhibitors
Furr, B. J. A. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8693-1_9
“The medium time to symptom recurrence was also significantly longer in the combination group [ 45 ].”
BackgroundHormontherapie bei gynäkologischen, nichtmalignen Erkrankungen: Endometriose, Myome
Schäfer, S. D., Braun, J. M., & Kiesel, L. (2013) · Der Gynäkologe · doi:10.1007/s00129-012-3071-0
Aromatasehemmer in der Therapie der Endometriose
Juhasz-Böss, I., Treeck, O., Malik, E., & Ortmann, O. (2006) · Gynäkologische Endokrinologie · doi:10.1007/s10304-006-0156-7 · Cited by 1
“Keine der Patientinnen mit einem Knochendichteverlust entwickelte eine Osteoporose [35].”
BackgroundInfluentialPotential use of aromatase inhibitors in gynecology
Lukic, J., & Tulandi, T. (2006) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.1.1.41
New opportunities in premenopausal breast cancer: goserelin (‘Zoladex’) plus aromatase inhibition
Jakesz, R. (2006) · Breast Cancer Online · doi:10.1017/s1470903105004323
“The effects of goserelin plus anastro-zole vs. goserelin alone have been examined in two Phase II studies in premenopausal women, one in patients with endometriosis [19] and one in patients with breast cancer [20].”
Chronische Endometriose: medikamentöse Therapie
Schäfer, S. D., & Kiesel, L. (2010) · Der Gynäkologe · doi:10.1007/s00129-010-2591-8
Pharmacological treatment of endometriosis: update from recent clinical trials
Ferrero, S., Remorgida, V., & Venturini, P. L. (2011) · Clinical Investigation · doi:10.4155/cli.10.4
Ziegler, E. (2007) · Publications of the UdS (Saarland University) · doi:10.22028/d291-22367
Hormonal strategy for the primary or secondary treatment of endometriosis
Lazzeri, L., Tosti, C., Pinzauti, S., Orlandini, C., Luisi, S. V., & Petraglia, F. (2012) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.12.46
Use of aromatase inhibitors in gynecology
Elnahhas, I. M., & Mitwally, M. F. (2010) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.10.10
Newer treatment modalities in endometriosis: systematic review
Gupta, S., Chandra, A., Choi, A. H., Surti, N., & Agarwal, A. (2009)
Role of Aromatase Inhibitors in the Treatment of Endometriosis
Baştu, E. (2014) · The Annals of Clinical and Analytical Medicine · doi:10.4328/jcam.2782
Medikamentöse Therapie der Endometriose
Imesch, P., Samartzis, E. P., & Fink, D. A. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-74219
Imesch, P., Samartzis, E. P., & Fink, D. A. (2012)
Drug therapy in the treatment of endometriosis
Popov, А. А., Slobodyanyuk, B. A., Мананникова, Т. Н., Fedorov, А. А., Чантурия, Т. З., & Zingan, S. I. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-2-86-91 · Cited by 2
Metadata
- Authors
- Soysal, S.
- Affiliations
- Pamukkale Üniversitesi Hastaneleri (TR)
- Corresponding author
- Soysal, S.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-01
- Volume
- 19
- Issue
- 1
- Pages
- 160-167
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2149342667
- Cited by
- 227
- References
- 24
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 12 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 8 · 2018: 9 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 7 · 2013: 10 · 2012: 12
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- endometriosis, goserelin, anastrozole, GnRH analogues, aromatase inhibitors, combination endocrine therapy, conservative surgery, symptom recurrence, bone mineral density, lumbar spine, estrogen synthesis, premenopausal women
- MeSH terms
- Anastrozole, Adult, Drug Administration Schedule, Drug Therapy, Combination, Endometriosis, Enzyme Inhibitors, Estradiol, Female, Humans, Menopause, Nitriles, Palliative Care, Postoperative Care, Quality of Life, Severity of Illness Index, Triazoles, Bone Density, Survival Analysis, Treatment Outcome, Goserelin, Patient Selection, Aromatase Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.